|
|
|
|
| Symbol(s): |
IMGN |
| Date: |
24-May-13 |
| Author: |
Hunter Orr |
| Contributor: |
Alpha Street Research |
| Title: |
IMGN - ImmunoGen Inc - Downgraded to a Sell - Company Analysis and ASR Ranking Report |
| Document Size: |
9 pages |
| Price: |
$24 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $24. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| www.AlphaStreetResearch.com - Full Coverage of 3,000 U.S. equities. Reports include Financials, Ratios, Competitor Comparison, and our proprietary ASR Ranking indicating Buy/Sell/Hold. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's tumor activated prodructs deliver chemotherapy specifically to a tumor. ImmunoGen has three drugs in clinical trials and is negotiating to take a drug into phase II trial. These products are being tested for the treatment of...
| | |
|
|
